- Home
- FFWM vs ZURA Comparison
FFWM vs ZURA Comparison
Compare FFWM & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFWM | ZURA |
|---|---|---|
| Founded | 1990 | 2022 |
| Country | United States | United States |
| Employees | 485 | 30 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.9M | 595.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | FFWM | ZURA |
|---|---|---|
| Price | $5.73 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $6.17 | ★ $11.78 |
| AVG Volume (30 Days) | ★ 578.3K | 520.3K |
| Earning Date | 04-29-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,373,000.00 | N/A |
| Revenue This Year | $56.34 | N/A |
| Revenue Next Year | $10.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $0.99 |
| 52 Week High | $6.72 | $7.25 |
Technical Indicators
Market Signals| Indicator | FFWM | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 36.66 |
| Support Level | $5.44 | $3.33 |
| Resistance Level | $5.95 | $5.75 |
| Average True Range (ATR) | 0.20 | 0.53 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 40.27 | 3.73 |
Price Performance
Historical ComparisonAbout FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.